CN102821777B - 神经丝肽用于神经胶质瘤的治疗的用途 - Google Patents

神经丝肽用于神经胶质瘤的治疗的用途 Download PDF

Info

Publication number
CN102821777B
CN102821777B CN201080061959.6A CN201080061959A CN102821777B CN 102821777 B CN102821777 B CN 102821777B CN 201080061959 A CN201080061959 A CN 201080061959A CN 102821777 B CN102821777 B CN 102821777B
Authority
CN
China
Prior art keywords
peptide
use according
nfl
cells
tbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080061959.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102821777A (zh
Inventor
J·埃耶
A·彼得森
J·巴尔赛优
R·贝格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Institution for the Advancement of Learning
Universite dAngers
National Institute of Health Sciences
Original Assignee
Royal Institution for the Advancement of Learning
Universite dAngers
National Institute of Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Institution for the Advancement of Learning, Universite dAngers, National Institute of Health Sciences filed Critical Royal Institution for the Advancement of Learning
Publication of CN102821777A publication Critical patent/CN102821777A/zh
Application granted granted Critical
Publication of CN102821777B publication Critical patent/CN102821777B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201080061959.6A 2009-12-14 2010-12-14 神经丝肽用于神经胶质瘤的治疗的用途 Active CN102821777B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28620709P 2009-12-14 2009-12-14
EP09306227A EP2332560A1 (en) 2009-12-14 2009-12-14 Use of a neurofilament peptide for the treatment of glioma
EP09306227.1 2009-12-14
US61/286,207 2009-12-14
PCT/EP2010/069663 WO2011073207A1 (en) 2009-12-14 2010-12-14 Use of a neurofilament peptide for the treatment of glioma

Publications (2)

Publication Number Publication Date
CN102821777A CN102821777A (zh) 2012-12-12
CN102821777B true CN102821777B (zh) 2014-12-17

Family

ID=42133636

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080061959.6A Active CN102821777B (zh) 2009-12-14 2010-12-14 神经丝肽用于神经胶质瘤的治疗的用途

Country Status (7)

Country Link
US (2) US9446092B2 (enExample)
EP (2) EP2332560A1 (enExample)
JP (1) JP5806679B2 (enExample)
CN (1) CN102821777B (enExample)
CA (1) CA2784091C (enExample)
IN (1) IN2012DN05143A (enExample)
WO (1) WO2011073207A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire
EP2959913A1 (en) * 2014-06-23 2015-12-30 Universite D'angers Use of a neurofilament peptide for targeting neural stem cells
JP6612063B2 (ja) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 悪性神経膠腫分子標的ペプチド
US10550388B2 (en) * 2017-08-15 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Targeting pleiotrophin signaling to limit high-grade glioma invasion
CN108490191B (zh) * 2018-03-13 2019-04-16 首都医科大学附属北京地坛医院 神经丝蛋白轻链在梅毒血液检测中的应用
WO2020074691A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
EP4593865A1 (en) * 2022-09-30 2025-08-06 Gliocure Pharmaceutical composition comprising nfl-tbs40-63peptide, variants or salts thereof and alanine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221476A1 (en) * 2004-05-04 2009-09-03 Universite D'angers Peptide Capable of Altering Tubulin Polymerization and use Thereof for Inhibiting Cell Proliferation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221476A1 (en) * 2004-05-04 2009-09-03 Universite D'angers Peptide Capable of Altering Tubulin Polymerization and use Thereof for Inhibiting Cell Proliferation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neurofilaments Bind Tubulin and Modulate Its Polymerization;Arnaud Bocquet et al;《The Journal of Neuroscience》;20090902;第29卷(第35期);第11043-11054页 *

Also Published As

Publication number Publication date
JP2013513646A (ja) 2013-04-22
US9446092B2 (en) 2016-09-20
CA2784091C (en) 2020-08-11
US20170000846A1 (en) 2017-01-05
EP2512499B1 (en) 2015-09-16
CN102821777A (zh) 2012-12-12
JP5806679B2 (ja) 2015-11-10
EP2332560A1 (en) 2011-06-15
CA2784091A1 (en) 2011-06-23
EP2512499A1 (en) 2012-10-24
US20130004429A1 (en) 2013-01-03
IN2012DN05143A (enExample) 2015-10-23
WO2011073207A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
CN102821777B (zh) 神经丝肽用于神经胶质瘤的治疗的用途
Li et al. Angiotensin AT2 receptor protects against cerebral ischemia‐induced neuronal injury
Adhihetty et al. Effect of denervation on mitochondrially mediated apoptosis in skeletal muscle
Li et al. Mesencephalic astrocyte‐derived neurotrophic factor affords neuroprotection to early brain injury induced by subarachnoid hemorrhage via activating Akt‐dependent prosurvival pathway and defending blood‐brain barrier integrity
KR102436886B1 (ko) 신경퇴행성 장애
TWI400080B (zh) 藥物於治療患有青光眼和其他退化性眼疾之人的視力喪失上之用途
JP2018503632A (ja) 非分解性異常タンパク質の蓄積に関連した障害またはがんの治療のためのプロテアソーム阻害剤
Yu et al. Smart osteoclasts targeted nanomedicine based on amorphous CaCO3 for effective osteoporosis reversal
Xie et al. Retro-inverso bradykinin opens the door of blood–brain tumor barrier for nanocarriers in glioma treatment
Papini et al. Cardiomyocyte-targeting exosomes from sulforaphane-treated fibroblasts affords cardioprotection in infarcted rats
Donath et al. Interaction of ARC and Daxx: A novel endogenous target to preserve motor function and cell loss after focal brain ischemia in mice
Guo et al. Astroglial N‐myc downstream‐regulated gene 2 protects the brain from cerebral edema induced by stroke
US20170307623A1 (en) Compounds For Use As Imaging Agents
US20190076509A1 (en) Prevention and/or treatment of ischemia or ischemia/reperfusion injury
Zhang et al. The PERK pathway plays a neuroprotective role during the early phase of secondary brain injury induced by experimental intracerebral hemorrhage
Smyth et al. Increased interaction between connexin43 and microtubules is critical for glioblastoma stem-like cell maintenance and tumorigenicity
Li et al. Chondrocyte-targeted α-Solanine through HIF-1α regulating glycolysis to reduce the ferroptosis of chondrocyte in osteoarthritis
Pan et al. Temporal patterns and distribution of pyroptosis-related molecules and effects of human mesenchymal stem cells on pyroptosis following cerebral ischemia/reperfusion in rats
CN108586580A (zh) 细胞穿透肽dhyhpfs及作为细胞内运送载体的用途
KR20190020486A (ko) 진토닌을 포함하는 혈관의 투과성을 증가시키는데 사용하기 위한 조성물 및 그의 용도
CN120267849B (zh) 一种靶向双硫死亡的载6-氨基烟酰胺纳米材料及其制备方法和在卵巢癌中的应用
Carreño et al. BDNF-TrkB pathway mediates NMDA receptor NR2B subunit phosphorylation in the supraoptic nuclei following progressive dehydration
Yu et al. Smart osteoclasts targeted nanomedicine based on amorphous CaCO
RU2744453C2 (ru) Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний
EP4252750A1 (en) Pharmaceutical preservation of creb activation in the treatment of alzheimer's disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant